Skip to main content
Log in

How Long Can an Escalation of Dose Override Tolerance to the Hypotensive Efficacy of Nitroglycerin Infusion in Coronary Care Patients

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Summary. Tolerance to nitroglycerin infusion (NG) can be overridden by dose escalation. The aim of this study was to define for how long it can be done for hypotensive efficacy of NG, in a coronary care setting.

A prospective trial with an intra-individual therapeutic comparison was performed in 60 patients with acute myocardial infarction or unstable angina. Initial efficacy of NG was confirmed by a 10% blood pressure decrease (measured by cuff). Seventy-two-hour NG infusion was interrupted, for 30 minutes, every 12 hours. If blood pressure increased by 10% after infusion interruption, the infusion was continued at the previous rate. If blood pressure did not increase (detected tolerance<197>weakened efficacy of NG), the dose was increased until pressure decreased by 10% and the infusion was continued at the new dose. Failure to achieve hypotensive response, despite a 5-fold dose increase, indicated onset of resistance<197>completely lost hypotensive efficacy of NG.

The majority of patients (49 out of 55) who developed tolerance, developed it during the first 36 hours, while the majority of those who developed resistance (33 out of 40), developed it within 60 hours of the infusion. Tolerance was overridden by dose escalation in 41 out of 55 patients, which was repeated in 31 patients. Complete restoration of NG action was possible over 24 hours in half the patients, and over 48 hours in one third of the patients. Three out of 34 patients who developed tolerance before the 13th hour did not develop resistance during the following 60 hours of dose up-titration.

The conclusion is that tolerance to NG can be overridden by dose escalation in the majority of patients for a significant period of time, which is useful in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Rapaport E. Pharmacologic therapy for acute myocardial infarction. Which agent, how much, how soon, how long? Postgraduate Med 1997;102:143–145.

    Google Scholar 

  2. Thadani U. Secondary preventive potential of nitrates in ischaemic heart disease. Eur Heart J 1996;17(Suppl F):30–36.

    Google Scholar 

  3. Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther 1997;10:735–742.

    Google Scholar 

  4. Jugdutt Bl, Warnica JW. Tolerance with low dose intravenous nitroglycerin therapy in acute myocardial infarction. Am J Cardiol 1989;64:581–587.

    Google Scholar 

  5. Dupuis J, Lalonde G, Lebeau R, Bichet D, Rouleau JL. Sustained beneficial effect of a seventy-two hour intravenous infusion of nitroglycerin in patients with severe chronic congestive heart failure. Am Heart J 1990;120:625–637.

    Google Scholar 

  6. Thadani U, Opie LH. Nitrates for unstable angina. Cardiovasc Drugs Ther 1994;8:719–726.

    Google Scholar 

  7. Milicevic G. Molecular mechanism of glyceryl trinitrate action and tolerance development. Acta Pharm 1992;42:1–8.

    Google Scholar 

  8. Robertson RM, Robertson D. Drugs used for the treatment of myocardial ischemia. In: Hardman JG, Limpbird LE, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996:765.

    Google Scholar 

  9. Kaplan KJ, Taber M, Teagarden JR, Parker M, Davison R. Association of met-hemoglobinemia and intravenous nitroglycerin administration. Am J Cardiol 1985;55:181–183.

    Google Scholar 

  10. Makhoul N, Dakak N, Flugelman MY, et al. Nitrate tolerance in heart failure: Differential venous, pulmonary and systemic arterial effects. Am J Cardiol 1990;65:28J–31J.

    Google Scholar 

  11. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923–931.

    Google Scholar 

  12. Milicevic G, Vrhovac B, Planinc D. A dynamical model for the separation of secondary resistance from tolerance to nitroglycerin infusion. Int J Clin Pharm Ther Toxicol 1993;31:12–17.

    Google Scholar 

  13. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988;77:1376–1384.

    Google Scholar 

  14. Milicevic G, Planinc D, Planinc-Peraica A, Vrhovac B. A high incidence of tolerance to hypotensive effect of low nitroglycerin dose detected by cyclic interruption of a nitroglycerin infusion. Croat Med J 1993;34:60–65.

    Google Scholar 

  15. Karlberg KE, Saldeen T, Wallin R, Henriksson P, Nyquist O, Sylven C. Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: double-blind placebo-controlled study. J Int Med 1998;243:25–31.

    Google Scholar 

  16. Varriale P, David WJ, Chryssos BE. Hemodynamic resistance to intravenous nitroglycerin in severe congestive heart failure and restored response after diuresis. Am J Cardiol 1991;68:1400–1402.

    Google Scholar 

  17. Thadani U, Sharma M, Thompson D, Prasad R, Goli V, Corn C. Intravenous nitroglycerin and tolerance in unstable angina. Circulation 1987;76(Suppl IV):IV-128.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milicevic, G., Goldner, V., Vrhovac, B. et al. How Long Can an Escalation of Dose Override Tolerance to the Hypotensive Efficacy of Nitroglycerin Infusion in Coronary Care Patients. Cardiovasc Drugs Ther 13, 531–536 (1999). https://doi.org/10.1023/A:1007831821716

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007831821716

Navigation